TAVR vs. the Least Invasive Surgically Implanted Valve

Rapid-deployment surgically implanted valves are designed to make a surgeons’ job faster and easier, compared with conventional bioprostheses, which require several stitches. These valves, which shorten surgical times, could compete with transcatheter-implanted valves (transcatheter aortic valve replacement, TAVR).

TAVI vs la válvula quirúrgica menos invasiva

The German Aortic Valve Registry analyzed 16,473 patients who underwent surgical aortic valve replacement with either a current-generation rapid-release valve or current-generation TAVR between 2011 and 2017.

Results from both procedures and devices were compared after matching patients 1:1 using propensity score.

TAVR patients were older and had higher surgical risk scores than those who underwent surgery.

Patients who underwent surgical valve replacement with rapid-release valves suffered from more disabling stroke (1.7% vs. 1.1%; p = 0.03) and needed more transfusions (8.5% vs. 1.4%; p < 0.001) and dialysis (1.9% vs. 1.2%; p = 0.01). Besides that, they had lower pacemaker implantation rates than their TAVR counterparts (8.4% vs. 14.9%; p < 0.001). 

In-hospital mortality was similar (1.6% vs. 1.8%; p = 0.62) when analyzing raw data, but after propensity score matching, a significant advantage in favor of TAVR was found (1.7% vs. 0.6%; p = 0.003).


Read also: The Best Anticoagulant Agent for AF After TAVR.


Balloon-expandable rapid-release valves had lower residual gradients than balloon-expandable TAVR. The opposite was observed with self-expanding valves, with which rapid-release valves had higher gradients.

Conclusion

This large registry of patients with aortic stenosis showed that TAVR presents an advantage in terms of in-hospital mortality compared with surgery using rapid-release valves. Rapid-release surgically implanted valves were better than percutaneous valves only in terms of pacemaker implantation.

Hemodynamic results varied according to the release mechanism of the device.

j-jcin-2020.09.018

Título original: Transcatheter Versus Rapid-Deployment Aortic Valve Replacement. A Propensity-Matched Analysis From the German Aortic Valve Registry.

Referencia: Mohamed Abdel-Wahab et al. J Am Coll Cardiol Intv 2020;13:2642–54. https://doi.org/10.1016/j.jcin.2020.09.018.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....